The cancer biomarkers market is largely driven by the increasing global prevalence of cancer and a growing adoption of early diagnosis. According to the World Cancer Research Fund, in 2018, there were an estimated 18 million cancer cases around the world, out of which, 9.5 million cases were in men and 8.5 million in women. In the recent years, knowledge about cancer biomarker has increased by leaps and bounds, providing great opportunities for improving the management of cancer patients, by improving the efficiency of detection and efficacy of treatment. The need for cancer diagnosis has also been increasing over the years, with more than 11 million people being diagnosed with cancer every year. According to the Global Cancer Observatory 2018, the number is projected to increase to 27.5 new cancer cases by 2040. Due to the rising prevalence of cancer in every part of the world, various governments and research organizations have established various initiatives for cancer awareness that are illustrating broad approaches for preventing and monitoring cancer. This is likely to drive the market growth over the forecast period. In addition, the paradigm shift in the healthcare from disease diagnosis to the risk assessment or early diagnosis of the cancer especially in developed countries creating the need for development of novel cancer biomarkers and testing.

1. INTRODUCTION

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

5. MARKET SEGMENTATION

6. COMPETITIVE LANDSCAPE AND COMPANY PROFILES

7. MARKET OPPORTUNITIES AND FUTURE TRENDS